Misonix Inc

Misonix — Merger or Acquisition (July 2021)

10 slides from Misonix's merger presentation, Jul 29, 2021

  1. Slide 1: Bioventus' Acquisition of Misonix

    Bioventus’ Acquisition of Misonix July 29, 2021 Exhibit 99.4

  2. Slide 2: Transaction Details

    Transaction Details Transaction Terms In the transaction, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration based on an aggregate maximu

  3. Slide 3: Bioventus At a Glance and Key Investment Highlights

    Broad customer reach and market access Differentiated, segment leading products across three verticals Substantial body of peer reviewed clinical evidence Robust free cash flow conversion Experienced management team with a track record of value creation Bioventus offers clinically differentiated, co

  4. Slide 4: Misonix extends Bioventus' leadership across key franchises

    Misonix extends Bioventus’ leadership across key franchises and expands the breadth and depth of offerings Ultrasonic medical devices for the precise removal of hard and soft tissue Differentiated spine surgical / wound platform driving sustainable double-digit revenue growth within a $2B TAM Recurr

  5. Slide 5: Misonix Surgical and Wound products

    Surgical Wound ~$40M FY21 Revenue ~$34M FY21 Revenue Product Bone Resection Tumor Aspiration Wound Debridement Skin Substitutes Description Differentiated technology that allows for extremely precise cuts to reduce operating time and bleeding Provides tactile feedback to surgeon to prevent patient i

  6. Slide 6: Platform technology enabling organic and inorganic expansion

    Platform technology that enables additional organic and inorganic expansion opportunities Highly complementary product offerings leveraging combined sales infrastructure to drive revenue acceleration Accelerates top-line growth with strong financial returns Expected annualized cost synergies of $20M

  7. Slide 7: The "New" Bioventus

    The “New” Bioventus Products Expected Pro Forma ’21 BVS Rev. TalisMann TAM Pain Treatments Restorative Therapies Surgical Solutions ~$215M ~$170M $2B Global HA $6B Global PNS ~$8B $350M Global Bone Healing $1.75B Global Rehabilitation $1B Wound Care ~$3B $2.7B US Orthobiologics $600M Bone Resection

  8. Slide 8: A Significant Synergy Opportunity

    A Significant Synergy Opportunity Bioventus expects $20M expected annualized cost synergies by end of 2023 Bioventus expects significant potential revenue synergies Cost Synergies Growth Acceleration Improved scale of the combined organization Leverage across sales, marketing and market access platf

  9. Slide 9: Compelling Shareholder Value Creation

    Compelling Shareholder Value Creation Transformational Scale and Robust Growth Approximately $500M of forecasted pro forma 2021 revenues expected by Bioventus to grow double-digits Enhanced sales force leverage in both spine surgical and wound care Significant Synergy Potential Bioventus expects ann

  10. Slide 10: Additional Information

    Additional Information In connection with the proposed transaction, Bioventus and Misonix plan to file with the Securities and Exchange Commission (the “SEC”) and mail or otherwise provide to their respective stockholders a joint proxy statement/prospectus and other relevant documents in connection

Misonix — Merger or Acquisition (July 2021) on 6ix